Why is neoadjuvant chemoradiation therapy underused for locally advanced rectal cancer?

Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1317-1319. doi: 10.1080/17474124.2016.1246182. Epub 2016 Oct 19.

Authors

Chiara Molinari¹, Alessandro Passardi²

Affiliations

¹ a Department of Biosciences Laboratory , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS , Meldola , Italy.
² b Department of Medical Oncology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS , Meldola , Italy.

PMID: 27754713
DOI: 10.1080/17474124.2016.1246182

No abstract available

Keywords: Chemotherapy; multimodal treatment; neoadjuvant therapy; radiotherapy; rectal cancer.

Publication types

Editorial

MeSH terms

Age Factors
Chemoradiotherapy, Adjuvant / adverse effects
Chemoradiotherapy, Adjuvant / standards
Chemoradiotherapy, Adjuvant / statistics & numerical data*
Comorbidity
Guideline Adherence
Healthcare Disparities
Humans
Neoadjuvant Therapy / adverse effects
Neoadjuvant Therapy / standards
Neoadjuvant Therapy / statistics & numerical data*
Neoplasm Invasiveness
Neoplasm Staging
Patient Selection
Practice Guidelines as Topic
Practice Patterns, Physicians'* / standards
Rectal Neoplasms / mortality
Rectal Neoplasms / pathology
Rectal Neoplasms / therapy*
Risk Factors
Treatment Outcome